At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 65 enrolled
Drug / intervention
MSTT1041A +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating MSTT1041A and Placebo for Atopic Dermatitis. Completed, enrolled 65 participants across 21 sites in 3 countries.
Detailed Summary
This study will assess the efficacy and safety of MSTT1041A (astegolimab) in participants with moderate to severe atopic dermatitis (AD). The study consists of a screening period, a 16-week treatment period, and an 8-week follow-up period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesGermany, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartFeb 2019
Primary CompletionMar 2020
Study CompletionMay 2020
TodayJul 2026
First PostedNov 20, 2018
Enrollment StartFeb 6, 2019
Primary CompletionMar 11, 2020
Study CompletionMay 5, 2020
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.6 years ago
Interventions
MSTT1041Adrug
Participants will receive subcutaneous (SC) MSTT1041A
Placebodrug
Participants will receive SC placebo